Innovodigm, a med-tech innovator spun out of IIT Kharagpur, has raised ₹5.5 crore in seed funding, led by IAN Group with participation from PadUp Ventures. IAN contributed ₹4.5 crore to the round.
The startup plans to channel the funds into scaling infrastructure, expanding its core team, and preparing for third-party preclinical validation and upcoming clinical trials.
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is reimagining vaccine delivery through micro-array patch (MAP) technology—a needle-free, thermostable alternative to traditional injections.
“Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been fundamental to our scientific foundation. Our MAP platform reflects India’s ability to lead in affordable, scalable vaccine delivery that serves both national and global public health goals,” said Jhimli Manna, Co-founder & CEO of Innovodigm.
Unlike traditional vaccines that require refrigeration and syringes, Innovodigm’s thermostabilized patches can remain viable for up to 120 days at 40°C. This makes them a game-changer for rural outreach, eliminating cold-chain dependency, reducing medical waste, and avoiding needle-stick injuries.
The company’s MAP tech has earned national acclaim, having been selected as a Top 2 Technology at the Nano Electronics Showcase 2025 by the Ministry of Electronics & IT. Innovodigm has also signed a Material Transfer Agreement (MTA) with a leading Indian vaccine maker for third-party validation, with clinical trials expected in 2026.
Looking ahead, Innovodigm plans to adapt the patch for a range of vaccines, including measles, hepatitis, flu, and COVID-19 boosters. The company is also building local manufacturing hubs, enabling scalable production closer to where it’s needed most — particularly in low- and middle-income countries (LMICs).
In a time when global health equity is more vital than ever, Innovodigm is showing the world that Indian science can not only innovate — but lead.
